Market Overview

BMO Capital Markets Reiterates Underperform Rating, $30 PT on Zoetis on Avian Flu Scare

Share:
Related ZTS
Top Research Reports for UnitedHealth, Netflix & Pepsi
Celgene (CELG) Reports Data on Lupus Drug in Phase II Trial

In a report published Friday, BMO Capital Markets analyst Alex Arfaei reiterated an Underperform rating and $30.00 price target on Zoetis (NYSE: ZTS).

In the report, Arfaei noted, “Shares of Zoetis are weak today in part related to the 14 human cases of the H7N9 virus, an unusual strain of bird flu that has so far killed six people in China, which has in turn led the Chinese authorities to kill more than 20,000 birds from a live-poultry trading zone. Shanghai will temporarily close all its live poultry markets starting Saturday.”

Zoetis closed on Thursday at $31.84.

Latest Ratings for ZTS

DateFirmActionFromTo
Jun 2017Cantor FitzgeraldInitiates Coverage OnOverweight
Jun 2017BMO CapitalDowngradesOutperformMarket Perform
May 2017CL KingInitiates Coverage OnBuy

View More Analyst Ratings for ZTS
View the Latest Analyst Ratings

Posted-In: BMO Capital MarketsAnalyst Color Reiteration Analyst Ratings

 

Related Articles (ZTS)

View Comments and Join the Discussion!